EVENT TNGX-VOPIMETOSTAT-2026
SCORED SET evaluable
FLOOR floor_daraxonrasib_pfs six_month_pfs_rate >= 90 | Six-month progression-free survival rate in the efficacy-evaluable vopimetostat plus daraxonrasib PDAC population.
BAR bar_daraxonrasib_orr objective_response_rate >= 92 | Objective response rate in the efficacy-evaluable MTAP-deleted, RAS-mutant PDAC population receiving vopimetostat plus daraxonrasib.